Malignant Melanoma of Conjunctiva

Sobin, L.H.; Wittekind, Ch.

doi:10.1002/0471463752.tnmc49

Cited by 125 publications

(152 citation statements)

References 0 publications

Supporting

Mentioning

150

Contrasting

Order By: Relevance

“…The current (2009) tumour, node, metastases (TNM) cancer staging manual groups all node-positive patients into a single category (pN1) 48. However, there is evidence that the nodal burden of disease can further stratify patients in terms of prognosis and outcome.…”

Section: Metastatic Tumour Burden and Prognostic Histopathological Pamentioning

confidence: 99%

“…In organs such as the breast, the definition and significance of small metastatic deposits including micrometastases and isolated tumour cells is well established and incorporated into the TNM staging system 48. However, in relation to prostate cancer no such definitions exist, and risk grouping based on size is not part of the current staging system.…”

Section: Metastatic Tumour Burden and Prognostic Histopathological Pamentioning

confidence: 99%

See 1 more Smart Citation

Lymph node staging in prostate cancer: perspective for the pathologist

Prendeville

Kwast

2016

J Clin Pathol

View full text Add to dashboard Cite

Pelvic lymph node dissection (PLND) currently represents the gold standard method for nodal staging in the setting of localised prostate cancer and may also have a therapeutic benefit in certain patients. The histopathological evaluation of PLND specimens plays a critical role in accurate lymph node staging, however there is currently a lack of consensus regarding the optimum approach and no quality parameters are in place. In addition, there are no guidelines as to the handling of less commonly encountered nodal specimens such as those identified within the anterior fat pad. This summary provides an overview of pertinent issues regarding lymph node staging in prostate cancer, with a focus on the histopathological evaluation of resected nodal specimens. We hope that this review will further the discussion on how to achieve a more standardised approach to the processing and reporting of PLND specimens in the setting of prostate cancer.

show abstract

Section: Metastatic Tumour Burden and Prognostic Histopathological Pamentioning

confidence: 99%

Section: Metastatic Tumour Burden and Prognostic Histopathological Pamentioning

confidence: 99%

Lymph node staging in prostate cancer: perspective for the pathologist

Prendeville

Kwast

2016

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…The pathological staging of tumour extent (pT) is an assessment of locoregional parameters based on tumour size and local invasion mostly 1 2. In colorectal cancer, the pT stage recognises the extent of local invasion across the bowel wall.…”

Section: Introductionmentioning

confidence: 99%

“…The understanding was that more data should be collected to determine whether such subsets be adopted in the future 6 7. The 5th (TNM5) and 6th (TNM6) editions of the International Union against Cancer ( UICC) TNM classification of malignant tumours also do not recognise two subsets in the pT4 stage for colorectal cancer reporting 1 2. Interestingly, there has been a significant change in the recently revised CAP protocol for examination of colorectal cancer specimens with respect to the pT4 subsets 8.…”

Section: Introductionmentioning

confidence: 99%

“…In the UK, the Royal College of Pathologists' minimum dataset3 is agreed on the basis of TNM52 and does not accept the changes in TNM6,1 as the evidence base for the proposed changes in TNM6 does not warrant adoption 4 9–11. The UK position regarding the TNM6 centres around the issue of pericolonic and mesenteric tumour deposits 3 4 9–11.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Histopathological reporting of pT4 tumour stage in colorectal carcinomas: dotting the ‘i’s and crossing the ‘t’s

Swamy

2010

J Clin Pathol

View full text Add to dashboard Cite

A histological diagnosis of pT4 stage is used as the basis for offering adjuvant therapy to patients with colorectal cancer. Histological features diagnostic of pT4 stage in colorectal cancer include: (1) presence of tumour perforation, (2) invasion of an adjacent organ, (3) direct or discontinuous tumour extending to the non-peritonealised resection margin, and (4) tumour breaching the visceral peritoneum. Histological parameters to identify these features are not always entirely straightforward, making recognition of pT4 stage difficult at times. The presence of a cellular mesothelial reaction and/or inflammation extending to the serosal surface causes considerable confusion and may result in upstaging pT3 tumours. Conversely, involvement of the non-peritonealised margin in colonic tumours other than rectal cancers is at a risk of being understaged. Audits have shown that significant differences remain in the frequency with which serosal involvement is found between individual pathologists and multidisciplinary teams. The recognition of the criteria that define pT4a and pT4b subsets in pT4 stage to highlight different therapeutic connotations is not universally accepted, and this is likely to affect future reporting of the subsets. The review article highlights the contentious issues in histopathological recognition of pT4 tumour stage based on microscopic parameters in colorectal cancer.

show abstract

Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma

Hattangadi

Hong

Yeap

et al. 2009

Cancer

View full text Add to dashboard Cite

Background While adjuvant chemoradiation is commonly used in the United States for treatment of resected pancreatic cancer, there is no consensus on the benefit of this therapy as results from randomized trials are conflicting. We reviewed our experience in a consecutive, unselected series of patients treated with adjuvant 5-FU and radiation therapy for resected pancreatic adenocarcinoma. Methods 86 patients with resected pancreatic adenocarcinoma who underwent adjuvant therapy from 1998–2005 were identified. Medical records were reviewed. 93% of patients were treated with external beam RT to ≥ 50.4 Gy and 91% of patients received concurrent 5-FU by continuous infusion. 45% of patients went on to receive adjuvant gemcitabine. Results Median follow-up was 31 months (range 21–62) among the 20 patients still alive. Fewer than half of patients had positive (33%) or close (<1mm, 15%) resection margins. 81% of the tumors were T3; 66% had involved lymph nodes. The median overall survival (OS) for all patients was 22 months; negative lymph node status (p=0.016) was a significant prognostic factor for improved OS, while treatment with gemcitabine trended towards improved OS (p=0.080). Median disease-free survival (DFS) for all patients was 10 months, and treatment with gemcitabine (p=0.044) or any chemotherapy (p=0.047) were significant predictors of DFS. 75 patients (87%) had disease recurrence, the majority of whom recurred with peritoneal (55%) or liver (53%) metastases. Negative lymph nodes trended towards a lower rate of distant failure (p=0.060). Conclusions The median survival of this cohort is greater than that of the chemoradiation arms of the EORTC and ESPAC-1 trials, and comparable to the survival observed on the GITSG chemoradiation arm. Lymph node status and treatment with adjuvant chemotherapy were significant predictors of OS and DFS, respectively. Future survival improvements should be directed at reducing peritoneal and liver metastases. Further randomized trials are required to define the role of adjuvant therapy for pancreatic adenocarcinoma.

show abstract

Malignant Melanoma of Conjunctiva

Abstract: The TNM system is used to describe and classify cancer stages and progression based on the assessment of three components: T The extent of the primary tumour N The absence or presence and extent of regional lymph node metastasis M The absen… Show more

Cited by 125 publications

References 0 publications

Lymph node staging in prostate cancer: perspective for the pathologist

Lymph node staging in prostate cancer: perspective for the pathologist

Histopathological reporting of pT4 tumour stage in colorectal carcinomas: dotting the ‘i’s and crossing the ‘t’s

Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma

Contact Info

Product

Resources

About